文献速递妇科

III-IVA期子宫内膜癌辅助治疗选择:放化疗与化疗的比较分析

Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy.
PubMed 文献 · Gynecol Oncol · 2024-01-20

回顾性分析2家三级机构2010至2021年184例III-IVA期子宫内膜癌患者,比较单纯化疗(89例)与放化疗(95例)的失败模式与生存。中位随访54.8个月,放化疗组5年无复发生存率69.2% vs 化疗组56.3%(P=0.038),5年总生存率86.1% vs 78.9%(P=0.357)。

要点

  • 放化疗组5年无复发生存率69.2% vs 化疗组56.3%(P=0.038)。
  • 放化疗组盆腔复发10.5%、腹主动脉旁复发6.3%,均低于化疗组(29.2%、20.2%)。
  • 两组5年总生存率无显著差异(86.1% vs 78.9%,P=0.357)。

核心结论

  • 本研究提示辅助放化疗对III-IVA期子宫内膜癌患者具有潜在获益。
  • 作者认为需要纳入分子分型,以为此类患者制定最佳个体化辅助治疗策略。

研究设计与样本

  • 回顾性分析2家三级机构2010至2021年收治的184例III-IVA期子宫内膜癌患者。
  • 所有患者接受标准初次手术,术后接受单纯化疗(n=89)或放化疗(n=95)辅助治疗。
  • 比较化疗组与放化疗组的失败模式、无复发生存期和总生存期。

主要发现

  • 中位随访54.8个月,多数患者接受了盆腔(94.6%)或腹主动脉旁(75.5%)淋巴结清扫。
  • 5年无复发生存率放化疗组69.2% vs 化疗组56.3%(P=0.038)。
  • 5年总生存率放化疗组86.1% vs 化疗组78.9%(P=0.357)。
  • 盆腔复发率化疗组29.2% vs 放化疗组10.5%,腹主动脉旁复发率化疗组20.2% vs 放化疗组6.3%,化疗组均显著更高。
  • 远处复发率放化疗组23.2% vs 化疗组14.6%,但5年远处复发累积发生率两组无显著差异(放化疗组28% vs 化疗组35%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal adjuvant treatment for patients with locally advanced endometrial cancer (EC) remains debatable. We comparatively analyzed recurrence patterns and survival outcomes in patients with stage III-IVA EC treated with adjuvant chemotherapy (CT) exclusively or combined with radiotherapy (CRT). METHODS: We retrospectively analyzed 184 patients treated for stage III-IVA EC at 2 tertiary institutions between 2010 and 2021. All patients underwent standard primary surgery and received either CT alone (n = 89) or CRT (n = 95) as an adjuvant treatment. We compared the failure patterns, recurrence-free survival (RFS), and overall survival (OS) between the CT and CRT groups. RESULTS: The median follow-up period was 54.8 months. Most patients underwent pelvic (94.6%) or para-aortic (75.5%) lymphadenectomies. The 5-year RFS was 69.2% with CRT versus 56.3% with CT (P = 0.038), and 5-year OS was 86.1% versus 78.9% (P = 0.357). Pelvic and para-aortic recurrence rates were significantly higher in the CT group (pelvic: 29.2%; para-aortic: 20.2%) than in the CRT group (pelvic: 10.5%; para-aortic: 6.3%). The CRT group showed a higher rate of distant recurrence (CRT, 23.2% vs. CT, 14.6%) however, the 5-year cumulative incidence of distant recurrence was not significantly different between the two groups (CRT, 28% vs. CT, 35%). CONCLUSIONS: This study highlights the potential benefits of adjuvant CRT in patients with stage III-IVA EC. The incorporation of molecular classification is necessary to derive optimal personalized adjuvant treatment strategies for this patient population.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Kim HJ, Lee J, Lee KB, et al. Choosing the right adjuvant therapy for stage III-IVA endometrial cancer: A comparative analysis of chemoradiotherapy and chemotherapy. Gynecol Oncol. 2024. PMID: 38246045. doi:10.1016/j.ygyno.2024.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。